{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:06:57Z","timestamp":1788934017368,"version":"build-2803163510"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Infantile hemangiomas (IH) are the most common childhood vascular tumors, potentially complicated by ulceration and permanent functional or aesthetic sequelae. Current treatments include corticosteroids, \u03b2-blockers, and lasers, among others, existing evidence relies predominantly on direct pairwise comparisons. Consequently, the relative benefits and risks across these modalities remain inadequately defined. We conducted a systematic review and network meta-analysis (NMA) evaluating pharmacologic, laser, and combination therapies for IH to establish treatment hierarchies and inform clinical practice and future guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following a PROSPERO-registered protocol (CRD420261388356), we searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to 1 March 2026, for randomized controlled trials comparing various interventions for IH. The primary endpoint was excellent response rate. Secondary outcomes included other response rates, VAS\/HAS changes, healing time, treatment emergent adverse events, and recurrence. After independent risk-of-bias assessment (RoB2) and data extraction, we performed a random-effects NMA. Treatments were ranked using SUCRA probabilities, and evidence certainty was appraised via GRADE and CINeMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The synthesis comprised 25 trials (2044 patients) evaluating 16 distinct interventions. Risk of bias was low in six trials, raised \u201csome concerns\u201d in 14, and high in 5. Overall, the evidence body was of moderate certainty. Regarding the primary endpoint, intralesional bleomycin combined with oral propranolol yielded significantly higher excellent response rates than oral propranolol alone (RR = 1.55, 95% CI 1.28\u20131.89; high certainty). Topical timolol with intralesional lauromacrogol (RR = 7.98, 95% CI 1.52\u201341.79) and oral propranolol with corticosteroids (RR = 2.00, 95% CI 1.03\u20133.88) showed higher excellent response rates, supported by moderate-certainty evidence. No statistically significant differences in adverse-event incidence were detected across evaluated regimens, but the safety data were limited. Oral atenolol was associated with numerically lower recurrence rates compared to oral propranolol, but the difference did not reach statistical significance (RR = 0.64, 95% CI 0.32\u20131.28; moderate certainty).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Oral propranolol remains the standard of care for IH. However, our analysis shows that some combination regimens showed favorable efficacy for excellent clinical response. Still, sparse comparative data and low-certainty evidence currently obscure the optimal combination strategy. Defining precise risk-benefit profiles requires rigorous head-to-head trials utilizing uniform outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registeration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261388356<\/jats:ext-link>\n                      ; Identifier: CRD420261388356.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1882566","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:39:27Z","timestamp":1788932367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment"],"prefix":"10.3389","volume":"17","author":[{"given":"Mingxuan","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Children\u2019s Medical Center, the First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children\u2019s Medical Center, the First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children\u2019s Medical Center, the First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children\u2019s Medical Center, the First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.xps.0000482654.21247.63","article-title":"Oral versus topical propranolol for management of superficial infantile hemangiomas","volume":"13","author":"Abdel Wahab","year":"2017","journal-title":"Ann. Pediatr. Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00431-015-2561-1","article-title":"Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma","volume":"174","author":"Aly","year":"2015","journal-title":"Eur. J. Pediatr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4103\/ijd.ijd_867_22","article-title":"Comparing the effectiveness of propranolol versus atenolol in inducing clinical clearance in the treatment of infantile haemangioma: a randomised controlled trial","volume":"68","author":"Ashraf","year":"2023","journal-title":"Indian J. Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5070\/d32612051348","article-title":"Clinical evaluation of infantile hemangiomas treated with atenolol","volume":"26","author":"Ballona","year":"2020","journal-title":"Dermatol Online J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/jamaoto.2013.6723","article-title":"Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial","volume":"140","author":"Bauman","year":"2014","journal-title":"JAMA Otolaryngology - Head Neck Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/js9.0000000000000324","article-title":"Indications for surgical resection of complicated infantile hemangiomas in the \u03b2-blocker's era: a single-institution experience from a retrospective cohort study","volume":"109","author":"Beqo","year":"2023","journal-title":"Int. J. Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ad.2019.03.015","article-title":"Oral atenolol for infantile hemangioma: case series of 46 infants","volume":"111","author":"Calder\u00f3n-Castrat","year":"2020","journal-title":"Actas Dermosifiliogr. Engl. Ed."},{"key":"B8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1542\/peds.2007-2767","article-title":"Growth characteristics of infantile hemangiomas: implications for management","volume":"122","author":"Chang","year":"2008","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/00034894221089758","article-title":"Should propranolol remain the Gold standard for treatment of infantile hemangioma? A systematic review and meta-analysis of propranolol versus atenolol","volume":"132","author":"Chen","year":"2023","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/gpbjnl\/qzag023","article-title":"Single-cell RNA sequencing discovered subtypes associated with angiogenesis and propranolol treatment in infantile hemangioma","author":"Chen","year":"2026","journal-title":"Genomics Proteomics Bioinforma."},{"key":"B11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.12788\/j.sder.2016.050","article-title":"Infantile hemangiomas, complications and treatments","volume":"35","author":"Cheng","year":"2016","journal-title":"Semin. Cutan. Med. Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41390-020-0917-3","article-title":"Randomised controlled trial: can topical timolol maleate prevent complications for small superficial infantile haemangiomata in high-risk areas?","volume":"88","author":"Cheng","year":"2020","journal-title":"Pediatr. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1542\/peds.2015-2485","article-title":"Diagnosis and management of infantile hemangioma","volume":"136","author":"Darrow","year":"2015","journal-title":"Pediatrics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12519-019-00327-2","article-title":"Risk factors for infantile hemangioma: a meta-analysis","volume":"16","author":"Ding","year":"2020","journal-title":"World J. Pediatr."},{"key":"B15","first-page":"657","article-title":"Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial","volume":"17","author":"Ehsani","year":"2014","journal-title":"Arch. Iran. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jaad.2025.07.017","article-title":"Paradigm shift in the management of infantile hemangiomas in the beta-blocker era: a retrospective cohort study","volume":"93","author":"Fernandez","year":"2025","journal-title":"J. Am. Acad. Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19765","DOI":"10.1038\/srep19765","article-title":"Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study","volume":"6","author":"Ge","year":"2016","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/archderm.140.8.963","article-title":"Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas","volume":"140","author":"George","year":"2004","journal-title":"Arch. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.bjoms.2015.09.005","article-title":"Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas","volume":"53","author":"Gong","year":"2015","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa0903036","article-title":"Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells","volume":"362","author":"Greenberger","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1710517","DOI":"10.3389\/fphar.2025.1710517","article-title":"Propranolol (1 mg\/kg\/day) with intralesional bleomycin versus propranolol monotherapy for infantile hemangioma: a randomized controlled trial","volume":"16","author":"Guo","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e172836","DOI":"10.1172\/jci172836","article-title":"Infantile hemangioma: the common and enigmatic vascular tumor","volume":"134","author":"Holm","year":"2024","journal-title":"J. Clin. Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70750","DOI":"10.1111\/jocd.70750","article-title":"A systematic review and meta-analysis of the efficacy and safety of propranolol versus other drugs in the treatment of infantile hemangioma","volume":"25","author":"Hu","year":"2026","journal-title":"J. Cosmet. Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e15907","DOI":"10.1111\/dth.15907","article-title":"Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: a meta-analysis of 10 studies","volume":"35","author":"Huang","year":"2022","journal-title":"Dermatol Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1515901","DOI":"10.3389\/fphar.2024.1515901","article-title":"Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e193039","DOI":"10.1172\/jci193039","article-title":"Unveiling the cholesterol-hemangioma axis: a path to new treatments","volume":"135","author":"Iruela-Arispe","year":"2025","journal-title":"J. Clin. Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1001\/jamaoto.2021.0454","article-title":"Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial","volume":"147","author":"Ji","year":"2021","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"B29","first-page":"71","article-title":"Comparison of efficacy between propranolol and steroid for infantile hemangioma","volume":"29","author":"Kashif","year":"2018","journal-title":"Med. Forum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamadermatol.2017.0250","article-title":"Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial","volume":"153","author":"Kim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas","volume":"143","author":"Krowchuk","year":"2019","journal-title":"Pediatrics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjd.13379","article-title":"Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas","volume":"172","author":"Langley","year":"2015","journal-title":"Br. J. Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/prs.0000000000007699","article-title":"Propranolol therapy in infantile hemangioma: it is not just about the beta","volume":"147","author":"Lee","year":"2021","journal-title":"Plast. Reconstr. Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/SCS.0000000000002221","article-title":"Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions","volume":"27","author":"Li","year":"2016","journal-title":"J. Craniofac Surg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1706048","DOI":"10.3389\/fphar.2025.1706048","article-title":"Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective","volume":"16","author":"Liang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/bcp.14196","article-title":"The effectiveness and safety of topical \u03b2-receptor blocker in treating superficial infantile haemangiomas: a meta-analysis including 20 studies","volume":"86","author":"Lin","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B37","first-page":"8951","article-title":"Combinational effect of pulsed dye laser and propranolol on treatment of superficial hemangioma","volume":"28","author":"Liu","year":"2017","journal-title":"Biomed. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1361105","DOI":"10.3389\/fped.2024.1361105","article-title":"Comparison of efficacy and safety between oral propranolol combined with and without intralesional injection of lauromacrogol for infantile hemangioma","volume":"12","author":"Ma","year":"2024","journal-title":"Front. Pediatrics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.jpedsurg.2013.08.020","article-title":"Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study","volume":"48","author":"Malik","year":"2013","journal-title":"J. Pediatr. Surg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3928\/01913913-20170703-12","article-title":"Combined oral and topical beta blockers for the treatment of early proliferative superficial periocular infantile capillary hemangioma","volume":"55","author":"Marey","year":"2018","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1525-1470.2011.01685.x","article-title":"Topical timolol for infantile hemangiomas: putting a note of caution in cautiously optimistic","volume":"29","author":"McMahon","year":"2012","journal-title":"Pediatr. Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.4103\/ijo.IJO_59_19","article-title":"To compare intralesional and oral propranolol for treating periorbital and eyelid capillary hemangiomas","volume":"67","author":"Mehta","year":"2019","journal-title":"Indian J. Ophthalmol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00383-003-1058-6","article-title":"Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations","volume":"19","author":"Muir","year":"2004","journal-title":"Pediatr. Surg. Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5966\/sctm.2015-0076","article-title":"Propranolol targets hemangioma stem cells via cAMP and mitogen-activated protein kinase regulation","volume":"5","author":"Munabi","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13052-022-01334-2","article-title":"Quality of life improving after propranolol treatment in patients with infantile hemangiomas","volume":"48","author":"Pensabene","year":"2022","journal-title":"Ital. J. Pediatr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamapediatrics.2021.4565","article-title":"Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial","volume":"176","author":"Pope","year":"2022","journal-title":"JAMA Pediatr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/archdermatol.2011.203","article-title":"Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis","volume":"147","author":"Price","year":"2011","journal-title":"Arch. Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.survophthal.2019.02.005","article-title":"Current treatment and management of infantile hemangiomas","volume":"64","author":"Satterfield","year":"2019","journal-title":"Surv. Ophthalmol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaad.2021.08.020","article-title":"Infantile hemangioma. Part 2: management","volume":"85","author":"Sebaratnam","year":"2021","journal-title":"J. Am. Acad. Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00441-014-1976-8","article-title":"\u03b2-Adrenergic receptor antagonists inhibit vasculogenesis of embryonic stem cells by downregulation of nitric oxide generation and interference with VEGF signalling","volume":"358","author":"Sharifpanah","year":"2014","journal-title":"Cell Tissue Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ced\/llae401","article-title":"Efficacy and safety of atenolol vs. propranolol for treatment of infantile haemangioma: a narrative review","volume":"50","author":"Shi","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B53","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3892\/etm.2012.654","article-title":"Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis","volume":"4","author":"Stiles","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.3892\/ol.2018.9493","article-title":"Short-term curative effect and safety of propranolol combined with laser in the treatment of infantile hemangiomas","volume":"16","author":"Sun","year":"2018","journal-title":"Oncol. Lett."},{"key":"B55","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/ijd.17062","article-title":"The prevalence, complications, and risk factors for infantile hemangioma: a systematic review and meta-analysis","volume":"63","author":"Sun","year":"2024","journal-title":"Int. J. Dermatol"},{"key":"B56","first-page":"164","article-title":"The therapeutic effect of propranolol with 1064 nm nd: YAG laser on proliferating hemangioma in body surface","volume":"28","author":"Tan","year":"2012","journal-title":"Zhonghua Zheng Xing Wai Ke Za Zhi"},{"key":"B57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/pde.12542","article-title":"Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study","volume":"32","author":"Tawfik","year":"2015","journal-title":"Pediatr. Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1542\/peds.2011-3683","article-title":"Early growth of infantile hemangiomas: what parents' photographs tell us","volume":"130","author":"Tollefson","year":"2012","journal-title":"Pediatrics"},{"key":"B59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2017.03.005","article-title":"Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment","volume":"185","author":"Wn\u0119k","year":"2017","journal-title":"Immunol. Lett."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/PRS.0b013e318267d3db","article-title":"Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells","volume":"130","author":"Wong","year":"2012","journal-title":"Plast. Reconstr. Surg."},{"key":"B61","first-page":"38","article-title":"Application of propranolol combined with laser in the treatment of infantile hemangioma and its effect on the appearance of hemangioma in children","volume":"16","author":"Yang","year":"","journal-title":"Chin. Foreign Med. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.19438\/j.cjoms.2018.03.017","article-title":"Expert consensus on the treatment of oral and maxillofacial hemangiomas and vascular malformations by lauromacrogol sclerotherapy","volume":"16","author":"Yang","year":"","journal-title":"China J. Oral Maxillofac. Surg."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/ijd.15015","article-title":"The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis","volume":"59","author":"Yang","year":"2020","journal-title":"Int. J. Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1684\/ejd.2013.2146","article-title":"Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial","volume":"23","author":"Zaher","year":"2013","journal-title":"Eur. J. Dermatol"},{"key":"B65","first-page":"932","article-title":"Clinical efficacy of lauromacrogol for local injection combined with timolol maleate in treatment of infantile hemangioma","volume":"45","author":"Zhang","year":"2022","journal-title":"Drug Evaluation Research"},{"key":"B66","first-page":"86","article-title":"Clinical efficacy and safety of topical timolol in the treatment of superficial infantile hemangioma","volume":"53","author":"Zhao","year":"2013","journal-title":"Shandong Med. J."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19438\/j.cjoms.2018.03.017","article-title":"Laser treatment of infantile hemangioma","volume":"22","author":"Ziad","year":"2023","journal-title":"J. Cosmet. Dermatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/archdischild-2012-302470","article-title":"The psychosocial impact of an infantile haemangioma on children and their parents","volume":"97","author":"Zweegers","year":"2012","journal-title":"Arch. Dis. Child."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:39:30Z","timestamp":1788932370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":68,"alternative-id":["10.3389\/fphar.2026.1882566"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1882566","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1882566"}}